PharmAsia News Notable Notes: CRO/CMO Divis Labs Has “Maximum Upside Potential” In India
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Kotak Institutional Equities has raised its price target for Hyderabad, India-based Divis Laboratories citing growing contract research and manufacturing as well as generic sales
You may also be interested in...
PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms
NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).